• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1 Contact Hour(s)

    Release Date

    Wednesday, June 17, 2020

    Offline Date

    Friday, June 17, 2022

    ACPE Expiration Date

    Friday, December 16, 2022

    Target Audience

    Pharmacist, Nurse

    Cost

    $4.00

    • Overview

      SGLT2 inhibitors and select GLP-1 RA are gaining attention as preferred agents in persons with type 2 diabetes who are at an elevated risk for cardiovascular disease.  The choice of therapy should ultimately be based on underlying cardiovascular risk, patient preferences, and the patient’s HbA1c goal.  This session seeks to explore the new cardiac and efficacy data related to available and emerging agents whose mechanisms of action are based on the incretin and sodium glucose co-transporter pathways. 

      Handouts

      • Slide Document :   19181H01_2pp.pdf
      • Slide Document :   19181H01_6pp.pdf

      Financial Support By

      PharmCon
    • Pharmacist

      Identify new cardiac safety and efficacy data related to available and emerging agents
      Differentiate between agents whose mechanisms of action are based on the incretin and sodium glucose cotransporter (SGLT2) pathways.
      Recognize the considerations and rationale for diabetes management, including combination therapy, that takes into account cardiac disease and other specific patient characteristics

      Nurse

      Identify new cardiac safety and efficacy data related to available and emerging agents
      Recognize the considerations and rationale for diabetes management, including combination therapy, that takes into account cardiac disease and other specific patient characteristics
      Differentiate between agents whose mechanisms of action are based on the incretin and sodium glucose cotransporter (SGLT2) pathways.
    • Activity Type

      Knowledge

      CE Broker

      20-704163

      Universal Activity Number

      Pharmacist 0798-0000-19-181-H01-P
      Nurse 0798-0000-19-181-H01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).